Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
U.S. President Donald Trump has announced a phased tariff plan reaching 200% on imported generic drugs by 2031 to encourage domestic manufacturing. Indian pharmaceutical companies warn that these measures will likely lead to higher medicine costs for American consumers.
Why it matters
The policy shift threatens to disrupt the global pharmaceutical supply chain and significantly impact India's export economy, potentially altering healthcare affordability in the U.S.
U.S. President Donald Trump has given generic pharmaceutical companies a two-year window to establish manufacturing facilities in the United States, warning that products imported after August 2028 could face tariffs of up to 200%.
The announcement, made on Wednesday (July 22, 2026) through a social media post, has significant implications for India, which sends more than a third of its pharmaceutical exports to the U.S. While Indian drugmakers sought to strike a cautious note, they warned that higher tariffs would ultimately increase medicine costs for American consumers.
Mr. Trump said the measure is intended to encourage generic drug production in the U.S. and reduce dependence on overseas supply chains.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in